Clinical Immunology · Autosomal Dominant Agammaglobulinemia 5

Long-Term Monitoring and Lung Health in AGM5

At a Glance

Long-term AGM5 care focuses on preventing lung damage by tracking breathing tests, respiratory infections, IgG trough levels, and symptoms. Clinicians use this information to decide when imaging, sputum testing, or changes to immunoglobulin treatment are needed.

Managing Agammaglobulinemia 5 (AGM5) is a long-term commitment. While your immediate focus may be on starting treatment, the long-term goal is respiratory surveillance—the proactive monitoring of your lungs to prevent permanent damage ^[1]. Because people with profound antibody deficiencies are prone to recurrent respiratory infections, staying ahead of these changes is the most important thing you can do for your future health ^[2].

Why Lung Monitoring is Critical

Even when you feel well, small amounts of inflammation from past infections can lead to bronchiectasis ^[1]. This is a condition where the bronchial tubes (the lungs’ airways) become permanently widened and scarred, making it harder to clear out mucus and germs ^[2].

Doctors use two primary tools to monitor your lungs:

Pulmonary Function Tests (PFTs): These are breathing tests (specifically spirometry) that measure how much air you can breathe out and how fast you can do it ^[3]. Establishing a baseline PFT and tracking changes over time is standard practice ^[3]^[4].
High-Resolution CT (HRCT): This is a detailed imaging scan that can see structural changes in the lungs that a standard X-ray might miss ^[5]. However, repeat imaging should be justified by your medical history, infection frequency, or a specific clinical question to limit unnecessary radiation exposure ^[5]^[6].

Tracking Your “Troughs” and Trends

Successful long-term care means looking at more than just one blood test. Your immunology team will track two main pieces of data over time:

IgG Trough Levels: This is the level of replacement antibodies in your blood just before your next infusion ^[7].
Infection Frequency: This is a record of how many times you needed antibiotics, how severe the infections were, and if they involved the lungs or sinuses ^[8].

If you are getting frequent infections despite treatment, your doctor may decide to individualize your care by increasing your dose or changing how often you receive your medicine ^[8]^[9].

Beyond the Lungs: Other Long-Term Considerations

While the lungs are the primary concern, certain situation-dependent findings may require evaluation. For instance, liver problems or cytopenias (low counts of red blood cells or platelets) can occur as complications of severe infections or as side effects of medications/treatments, rather than being expected direct features of AGM5 itself ^[10]^[11]. You will be monitored based on your specific symptoms, treatment plan, and risk factors.

If you develop a cough that produces mucus, your doctor may ask for a “sputum culture” to identify the exact bacteria so they can prescribe the most effective antibiotic ^[12].

The Psychological Aspect of Lifelong Therapy

Living with a rare disease and a lifelong treatment schedule can carry a significant treatment burden ^[13]. It is common to feel a sense of “infusion fatigue” or anxiety about the future ^[14].

Many patients find that the choice of treatment route—IVIG versus SCIG—impacts their quality of life ^[13]. Acknowledging the emotional impact is just as important as monitoring your lung function. Don’t hesitate to ask your care team for a referral to a mental health professional who specializes in chronic or rare diseases ^[15]^[16].

Common questions in this guide

How does AGM5 monitoring help protect my lungs?

People with AGM5 can develop recurrent respiratory infections, and repeated inflammation may damage the airways and cause bronchiectasis. Regular breathing tests, infection tracking, and clinically justified imaging help the care team find changes early and adjust care.

What tests are used to monitor lung health in AGM5?

Pulmonary function testing, especially spirometry, measures how much air you exhale and how quickly. A high-resolution CT scan can show structural changes that a standard chest X-ray may miss, but repeat CT is based on symptoms, infection history, or a specific clinical question to limit radiation.

What are IgG trough levels, and why are they checked?

An IgG trough is the antibody level measured just before your next immunoglobulin infusion. Your team considers this result together with infection frequency and severity to decide whether the dose or schedule needs to be individualized.

What should I do if I have a cough with mucus?

Tell your doctor about a new or worsening productive cough and changes in your usual mucus. They may order a sputum culture to identify bacteria and choose an antibiotic that is more likely to work.

Can IVIG or SCIG affect quality of life?

Yes. The route, schedule, and practical burden of intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) can affect work, travel, and treatment fatigue. Discuss your priorities with the care team, and ask for mental health support if treatment or the diagnosis is causing anxiety or isolation.

What other health problems may need monitoring in AGM5?

Depending on your symptoms, treatment, and risk factors, your clinicians may evaluate liver problems or low blood cell counts called cytopenias. These findings can result from severe infections or treatment effects and are not necessarily direct features of AGM5.

Get notified when new evidence is published on agammaglobulinemia 5, autosomal dominant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (16)

1
Evaluation of respiratory complications in patients with X-linked and autosomal recessive agammaglobulinemia.
Fekrvand S, Yazdani R, Olbrich P, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2020; (31(4)):405-417 doi:10.1111/pai.13228.
PMID: 32058651
2
Outcomes of X-Linked Agammaglobulinaemia Patients.
Shillitoe B, Duque JSR, Lai SHY, et al.
Journal of clinical immunology 2024; (45(1)):40.
PMID: 39541002
3
Multiple Breath Washout for Early Assessment of Pulmonary Complications in Patients With Primary Antibody Deficiencies: An Observational Study in Pediatric Age.
Secchi T, Baselli LA, Russo MC, et al.
Frontiers in pediatrics 2022; (10()):773751 doi:10.3389/fped.2022.773751.
PMID: 35656375
4
Bronchiectasis in Inborn Errors of Immunity: Prevalence, Predictors, and Cardiopulmonary Complications in a Genetically Characterized Cohort.
Marangu-Boore D, Myint-Hpu K, Kang E, et al.
Journal of clinical immunology 2026; (46(1)).
PMID: 42414785
5
Evaluation of pulmonary findings in patients with humoral immunodeficiency.
Karalı Z, Karalı Y, Çekiç Ş, et al.
Turk pediatri arsivi 2020; (55(2)):174-183 doi:10.14744/TurkPediatriArs.2020.46656.
PMID: 32684763
6
Pulmonary Computed Tomography Screening Frequency in Primary Antibody Deficiency.
Smits BM, Boland SL, Hol ME, et al.
The journal of allergy and clinical immunology. In practice 2024; (12(4)):1037-1048.e3 doi:10.1016/j.jaip.2023.12.047.
PMID: 38182096
7
[X-linked agammaglobulinemia: experience in a Portuguese hospital].
Fernandes A, Guedes M, Vasconcelos J, et al.
Anales de pediatria (Barcelona, Spain : 2003) 2015; (82(3)):166-71.
PMID: 25443324
8
Current Spectrum of Infections in Patients with X-Linked Agammaglobulinemia.
Paccoud O, Mahlaoui N, Moshous D, et al.
Journal of clinical immunology 2021; (41(6)):1266-1271 doi:10.1007/s10875-021-01043-1.
PMID: 33880703
9
Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach.
Pecoraro A, Crescenzi L, Granata F, et al.
International immunopharmacology 2017; (52()):136-142 doi:10.1016/j.intimp.2017.09.005.
PMID: 28898770
10
Common Variable Immunodeficiency and Liver Involvement.
Song J, Lleo A, Yang GX, et al.
Clinical reviews in allergy & immunology 2018; (55(3)):340-351 doi:10.1007/s12016-017-8638-z.
PMID: 28785926
11
Common Variable Immunodeficiency and Autoimmune Diseases: A Retrospective Study of 95 Adult Patients in a Single Tertiary Care Center.
Mormile I, Punziano A, Riolo CA, et al.
Frontiers in immunology 2021; (12()):652487 doi:10.3389/fimmu.2021.652487.
PMID: 34290696
12
X-linked agammaglobulinemia: ınvestigation of clinical and laboratory findings, novel gene mutations and prevention of ınfective complications in long-term follow-up.
Yıldırım İ, Topyıldız E, Bilgin RBG, et al.
American journal of clinical and experimental immunology 2021; (10(1)):37-43.
PMID: 33815962
13
The Development of a New Questionnaire to Measure the Burden of Immunoglobulin Treatment in Patients with Primary Immunodeficiencies: The IgBoT-35.
Jones GL, Williams K, Edmondson-Jones M, et al.
Patient preference and adherence 2020; (14()):1567-1584 doi:10.2147/PPA.S234669.
PMID: 32982185
14
Psychosocial Evaluation of Adults with Primary Immunodeficiency.
Gumusburun R, Altay S, Cengiz H, et al.
Journal of clinical immunology 2024; (44(3)):71 doi:10.1007/s10875-024-01671-3.
PMID: 38411715
15
Shared Decision-Making and Health-Related Quality of Life in the Diagnosis and Management of Patients With Inborn Errors of Immunity.
Lawrence MG, Kim VHD, Orange JS, Scherzer R
The journal of allergy and clinical immunology. In practice 2026; doi:10.1016/j.jaip.2026.07.010.
PMID: 42447994
16
Vulnerability beyond infection: Effects of peer victimization on quality of life and psychosocial well-being in inborn errors of immunity.
Meric Z, Durcan G, Coban ZB, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2026; (37(3)):e70318 doi:10.1111/pai.70318.
PMID: 41800593

This page is for informational purposes only and does not constitute medical advice. Your immunology and pulmonary care teams can tailor AGM5 monitoring and treatment to your specific situation.